# Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19

Study · id `cardio:ct-nct04416048` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04416048](<https://clinicaltrials.gov/study/NCT04416048>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04416048

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 111 participants.

## Technical summary

Registry record NCT04416048. Randomized; no masking; primary purpose prevention. Start 2020-11-30 (actual); primary completion 2021-07-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 111 participants (enrolled count; ClinicalTrials.gov record NCT04416048, source copy `cardio:ctgov-nct04416048-2022-01-12`, retrieved 2026-10-26)
- Started: 2020-11-30 (actual) (ClinicalTrials.gov record NCT04416048, source copy `cardio:ctgov-nct04416048-2022-01-12`, retrieved 2026-10-26)
- Primary completion: 2021-07-20 (actual) (ClinicalTrials.gov record NCT04416048, source copy `cardio:ctgov-nct04416048-2022-01-12`, retrieved 2026-10-26)
- Completion: 2021-07-20 (actual) (ClinicalTrials.gov record NCT04416048, source copy `cardio:ctgov-nct04416048-2022-01-12`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT04416048, source copy `cardio:ctgov-nct04416048-2022-01-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04416048-2022-01-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19
- Acronym: COVID-PREVENT
- Condition: COVID-19
- Intervention (Drug): Rivaroxaban
- Intervention (Other): Standard Of Care (SOC)
- Lead sponsor: Charite University, Berlin, Germany
- Lead sponsor class: OTHER
- Collaborator: Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
- Collaborator class: OTHER
- Collaborator: Bayer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: Charite University, Berlin, Germany (`cardio:org-charite-university-berlin-germany`)
- Registry lists this organization as a collaborator: Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) (`cardio:org-deutsches-zentrum-fur-herz-kreislauf-forschung-dzhk`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)

## Provenance

Content hash: 28dd16fa86473b420ef2c6ef2644ecde448de484e777aa842044091bb9fc53ea
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
